carbamazepine → KRAS → pancreatic ductal adenocarcinoma
Cross-domain hypothesis: Epilepsy drug → Pancreatic cancer outcome
Evidence network
The full set of scientific papers supporting this hypothesis, visualized as a force-directed graph. Each gray node is one paper; hover for the extracted claim, click to open it on PubMed.
View as text list
A→B papers (1)
- PMID 38446332 — Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status (2024) · in silico docking simulation conf 0.70
B→C papers (9)
- PMID 39999309 — Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients (2025) · pancreatic ductal adenocarcinoma conf 0.95
- PMID 39279379 — Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer (2024) conf 0.90
- PMID 35511415 — Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in <scp>FNA</scp>, biopsy, and resection specimens (2022) · in PDAC specimens conf 0.90
- PMID 34905283 — Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next‐generation sequencing acquired by endoscopic ultrasound–guided FNA and FNB (2021) · pancreatic ductal adenocarcinoma conf 0.80
- PMID 34665935 — Evaluation and diagnostic value of next‐generation sequencing analysis of residual liquid‐based cytology specimens of pancreatic masses (2021) · in residual LBC specimens of pancreatic masses conf 0.95
- PMID 30611220 — Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma (2019) · in pancreatic juice from patients with PDAC conf 0.80
- PMID 28675654 — Bioinformatory‐assisted analysis of next‐generation sequencing data for precision medicine in pancreatic cancer (2017) · in PDAC patients conf 0.90
- PMID 27929127 — Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells (2016) · mutated in >90% of cases conf 0.90
- PMID 26669280 — Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer (2015) · in genomic landscape of PDAC conf 0.80
Clinical trials
0 registered trials for carbamazepine in pancreatic ductal adenocarcinoma
Source: ClinicalTrials.gov
No registered trials found on ClinicalTrials.gov. This could indicate either an unexplored indication or a gap in registry coverage.
Search ClinicalTrials.gov →Provenance trace
Full audit trail of how this hypothesis was generated: source papers, extracted claims, bridging logic, embedding model, and scoring. Every step is recorded and reproducible.
Provenance trace
Audit trail · carbamazepine → KRAS → pancreatic ductal adenocarcinoma
10 source papers, 10 extracted claims, scored by Swanson ABC chain.
Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.
1Source papers10
2Extracted claims10
Each row is one structured triple extracted by deepseek-v4-flash (prompt v1_2026_05_07,
source: configured). Confidence is the LLM's self-rating.
- carbamazepinebinds_toKRASA→B
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
- KRASassociated_withpancreatic ductal adenocarcinomaB→C
No claims match this filter.
3Bridging logicSwanson ABC
- edge_support_log_ab
- log(ab + 1) =
0.693 - edge_support_log_bc
- log(bc + 1) =
2.303 - novelty_factor
1.000(no direct drug→outcome evidence — full novelty)- direct_a_to_c_count
0
4Embedding modelbge-m3
Embeddings are used at the L1 filtering stage to prune off-topic abstracts before claim extraction. They do not directly score the hypothesis.
- model
bge-m3- dim
1024- max_length
8192tokens- similarity_scores
- No per-hypothesis cosine scores stored.
5Final scoringhigh · 0.300
- method
swanson_abc_log_evidence_with_novelty_penalty- formula
score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)- raw score
0.2996- outreach score
0.2996- quality tier
high
Horizontal exploration
Similar hypotheses
Closest 8 of 1,618 hypotheses, ranked by hybrid score (50% bge-m3 embedding cosine · 40% drug/mediator/outcome overlap · 10% shared evidence papers).
- Alternative drug0.82Glyphosate→TP53→pancreatic ductal adenocarcinoma
Different drug, same disease outcome
- Alternative drug0.82AEV01→TP53→pancreatic ductal adenocarcinoma
Different drug, same disease outcome
- New indication0.81carbamazepine→KRAS→pancreatic cancer
Same drug + same mediator, different disease
- Alternative drug0.70Isochaihulactone→EGFR→pancreatic ductal adenocarcinoma
Different drug, same disease outcome
- Alternative drug0.70type-II kinase inhibitors→EGFR→pancreatic ductal adenocarcinoma
Different drug, same disease outcome
Show 3 more
- Alternative drug0.70mAb806→EGFR→pancreatic ductal adenocarcinoma
Different drug, same disease outcome
- Alternative drug0.70bergapten→EGFR→pancreatic ductal adenocarcinoma
Different drug, same disease outcome
- Alternative drug0.70Oxamate→EGFR→pancreatic ductal adenocarcinoma
Different drug, same disease outcome
The drug — carbamazepine
Evidence
Limited evidence base in our current extraction. Treat this hypothesis as a starting point for further literature review, not a settled conclusion.
A → B evidence: carbamazepine binds to KRAS
- PMID 38446332 Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status (2024)
B → C evidence: KRAS associated with pancreatic ductal adenocarcinoma
- PMID 39999309 Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients (2025)
- PMID 39279379 Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer (2024)
- PMID 35511415 Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in <scp>FNA</scp>, biopsy, and resection specimens (2022)
- PMID 34905283 Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next‐generation sequencing acquired by endoscopic ultrasound–guided FNA and FNB (2021)
- PMID 34665935 Evaluation and diagnostic value of next‐generation sequencing analysis of residual liquid‐based cytology specimens of pancreatic masses (2021)
- PMID 30611220 Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma (2019)
- PMID 28675654 Bioinformatory‐assisted analysis of next‐generation sequencing data for precision medicine in pancreatic cancer (2017)
- PMID 27929127 Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells (2016)
- PMID 26669280 Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer (2015)
References
All PMID-linked papers cited in the evidence network above, deduplicated and sorted by publication year.
- PMID 39999309 Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients (2025) B→C
- PMID 38446332 Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status (2024) A→B
- PMID 39279379 Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer (2024) B→C
- PMID 35511415 Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in <scp>FNA</scp>, biopsy, and resection specimens (2022) B→C
- PMID 34905283 Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next‐generation sequencing acquired by endoscopic ultrasound–guided FNA and FNB (2021) B→C
- PMID 34665935 Evaluation and diagnostic value of next‐generation sequencing analysis of residual liquid‐based cytology specimens of pancreatic masses (2021) B→C
- PMID 30611220 Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma (2019) B→C
- PMID 28675654 Bioinformatory‐assisted analysis of next‐generation sequencing data for precision medicine in pancreatic cancer (2017) B→C
- PMID 27929127 Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells (2016) B→C
- PMID 26669280 Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer (2015) B→C
Limitations & disclaimer
This hypothesis was generated algorithmically through cross-domain literature analysis and has not been experimentally validated. Treat it as a starting point for further investigation, not a therapeutic recommendation. For established knowledge about each entity, refer to the authoritative sources linked above (Wikipedia, DrugBank, UniProt, MeSH).